Study on Radium-223 and Docetaxel for Prostate Cancer Treatment

Inclusion Criteria

• Men aged 18 and older.
• Have a confirmed diagnosis of prostate cancer.
• Show signs of prostate cancer that has progressed despite treatment, based on specific medical tests.
• Have at least two bone lesions.
• Be in good overall health with a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have normal organ function and acceptable blood test results within 14 days before starting the study.
• Agree to use effective birth control methods during the study and for 30 days after the last dose of the study drug.
• Have low testosterone levels and continue hormone therapy if not surgically castrated.
• Have resolved any side effects from previous treatments to a mild level.
• Be willing and able to follow the study protocol, including attending follow-up visits and examinations.

Exclusion Criteria

• Have received other experimental treatments or cancer therapies within 4 weeks before starting the study.
• Have had recent external beam radiotherapy or need it immediately.
• Have used bone-targeting radiopharmaceuticals in the past.
• Have received chemotherapy for prostate cancer in the castration-resistant setting, except for up to 6 doses of docetaxel in the castration-sensitive setting without disease progression within 36 weeks.
• Have had four or more systemic treatments for castration-resistant prostate cancer.
• Have severe side effects from previous docetaxel treatment.
• Have had blood transfusions or growth factors within 4 weeks before starting the study.
• Have symptomatic lymph node disease causing swelling in the scrotum, penis, or legs.
• Have significant metastases in the lungs or liver.
• Have severe urinary or rectal symptoms from local disease.
• Have another active cancer, except for certain non-threatening types.
• Have spinal cord compression.
• Have bone marrow disorders.
• Have used certain medications or supplements affecting PSA levels within 4 weeks before starting the study.
• Have serious medical conditions that could make the study unsafe, such as uncontrolled infections, severe heart failure, or active infections with HIV, Hepatitis B, or Hepatitis C.